July 28, 2026 Guardant Health Launches Emotional Campaign Featuring Patrick Dempsey to Combat Colorectal Cancer Guardant Health launches a campaign featuring Patrick Dempsey, highlighting the importance of colorectal cancer screenings. The campaign promotes the Shield blood test, a non-invasive method that significantly increases screening rates among individuals aged 45 and over, aiming to save lives through early detection.
July 09, 2026 Guardant Health Announces Second Quarter 2026 Financial Results Release Guardant Health will release its financial results for Q2 2026 on July 30, followed by a conference call for in-depth insights. As a leader in precision oncology, their updates are crucial for investors and stakeholders.
July 01, 2026 UnitedHealth Group Expands Coverage for Guardant Health's Shield Blood Test Guardant Health's Shield blood test for colorectal cancer screening is now covered by UnitedHealth Group for members aged 45 and older. This non-invasive test addresses rising CRC rates and enhances access to innovative screening options for millions of Americans.
June 11, 2026 Guardant Health Secures FDA Approval for Groundbreaking Companion Diagnostic Guardant Health's Guardant360 CDx has received FDA approval as a companion diagnostic for HERNEXEOS, the first targeted therapy for HER2-mutant advanced NSCLC. This advancement underscores the significance of liquid biopsy in personalizing cancer treatment and improving patient outcomes.
May 28, 2026 Guardant Health Showcases Innovations in Liquid Biopsy Technology at ASCO 2026 Guardant Health is set to present 38 abstracts at ASCO 2026, highlighting innovations in liquid biopsy technology, including the FDA-approved Guardant360 test. The company aims to enhance cancer care through its advanced diagnostic tools and AI-driven insights.
May 20, 2026 Guardant Health Receives FDA Approval for Revolutionary Liquid Biopsy Test Guardant Health's Guardant360 Liquid CDx received FDA approval, marking a revolutionary advancement in cancer diagnostics with enhanced sensitivity and actionable insights. This test broadens access to precision oncology, providing critical information for effective treatment decisions.
May 07, 2026 Guardant Health Reports Robust Q1 2026 Results and Raises Revenue Guidance Guardant Health revealed robust Q1 2026 results, with a 48% revenue growth to $301.7 million, driven by oncology and screening segments. The company raised its 2026 revenue guidance, reflecting optimism for continued expansion in precision oncology.
April 30, 2026 Guardant Health and Nuvalent Forge Strategic Alliance to Enhance Oncology Diagnostics Guardant Health and Nuvalent have announced a multi-year collaboration to develop companion diagnostics and support the commercialization of innovative cancer therapies. This partnership aims to integrate advanced diagnostic tools with targeted therapies, significantly impacting cancer treatment and patient outcomes.
April 16, 2026 Guardant Health to Release First Quarter 2026 Financial Results Guardant Health will announce its Q1 2026 financial results on May 7, 2026, sparking interest in its innovative oncology solutions. A conference call will provide insights into performance and strategic initiatives.
March 30, 2026 Guardant Health's InfinityAI Supports ENHERTU® Approval in Japan Guardant Health's InfinityAI platform was pivotal in securing the approval of ENHERTU® in Japan for HER2-positive metastatic tumors. This innovative use of real-world evidence highlights a new era in precision oncology, enhancing patient access to targeted therapies.
March 18, 2026 Guardant Health Unveils Groundbreaking Research at AACR 2026 Guardant Health will present 28 abstracts at AACR 2026, highlighting innovations in tumor typing and liquid biopsy technologies. Key findings include high accuracy in cancer origin identification and expanded clinical actionability for metastatic patients.
March 16, 2026 Guardant Health Expands Access to Early Cancer Detection in Asia with Launch of Shield Multi-Cancer Detection Test Guardant Health has launched its Shield multi-cancer detection test in Asia, partnering with Manulife to improve early cancer detection for individuals aged 45+. This groundbreaking blood test aims to increase screening participation and improve health outcomes in a region where cancer is a significant health risk.
March 13, 2026 Guardant Health Survey Reveals Strong Support for Blood-Based Colorectal Cancer Screening Guardant Health's survey indicates overwhelming support for blood-based colorectal cancer screenings among Americans aged 45 and older. With 92% advocating for accessible testing, the Shield™ test is seen as a transformative solution to improve screening rates and reduce cancer mortality.
March 04, 2026 Guardant Health Launches Historic Coast-to-Coast Screening Tour Guardant Health has announced the Shield Across America initiative, a mobile screening tour aimed at increasing colorectal cancer screenings in over 100 communities. The initiative seeks to address the significant screening gap and improve accessibility to the FDA-approved Shield test, especially in underserved areas.
March 03, 2026 Patrick Dempsey Teams Up with Guardant Health to Promote Colorectal Cancer Screening Patrick Dempsey has joined forces with Guardant Health to raise awareness about colorectal cancer screening using the innovative Shield blood test. Aimed at individuals aged 45 and over, this blood test offers a convenient alternative to traditional methods, significantly improving screening compliance and early detection rates.
February 27, 2026 Guardant Health Makes Strategic Inducement Grants to Attract Talent Guardant Health has announced strategic inducement grants to attract new talent, including RSUs and stock options for 89 employees. This move supports their growth in precision oncology and commitment to innovation in cancer care.
February 19, 2026 Guardant Health Reports Strong 2025 Financial Results and Promising 2026 Outlook Guardant Health has reported strong financial results for 2025, with total revenue reaching $982 million, a 33% increase from 2024. The company anticipates continued growth in 2026, projecting revenues of $1.25 to $1.28 billion, driven by advancements in oncology and screening initiatives.
February 19, 2026 Guardant Health, Inc. Reports Strong Growth in 2025 Annual Financial Results Guardant Health, Inc. reported a significant 33% revenue growth in 2025, reaching $982 million. The company made strides in product innovation and international expansion, despite ongoing challenges with net losses and operational costs.
February 03, 2026 Guardant Health, Inc. Announces Participation in Key Investor Conferences Guardant Health, a leader in precision oncology, is set to participate in major investor conferences in early 2026. These events will provide opportunities for direct engagement with company leadership and insights into their innovative cancer care strategies. Investors can access live webcasts of the sessions on their website.
February 02, 2026 Guardant Health Unveils Groundbreaking Study on Molecular Residual Disease in Colon Cancer Guardant Health's landmark study reveals the potential of ctDNA testing in predicting recurrence for stage III colon cancer patients. By analyzing over 2,000 patients, the study demonstrates how the Guardant Reveal test can refine risk stratification and personalize treatment strategies, promising improved post-surgical outcomes.
January 29, 2026 Guardant Health Set to Announce Fourth Quarter and Full Year 2025 Financial Results Guardant Health is set to release its financial results for Q4 and the full year of 2025 on February 19, 2026. A conference call will follow to discuss these results and engage with investors. This announcement is pivotal for stakeholders invested in the oncology sector.
January 22, 2026 Guardant Health Secures FDA Approval for Revolutionary Colorectal Cancer Diagnostic Guardant Health's Guardant360® CDx received FDA approval as a companion diagnostic for identifying patients with BRAF V600E-mutant metastatic colorectal cancer. Supported by the BREAKWATER trial, this non-invasive test allows for timely and targeted treatment decisions, improving survival rates in a crucial patient demographic.
January 19, 2026 Guardant Health Partners with Merck to Revolutionize Cancer Diagnostics Guardant Health has partnered with Merck to enhance cancer diagnostics and therapy development through the Guardant Infinity™ platform. This collaboration focuses on clinical trial assays, new therapy exploration, and global commercialization, aiming to transform cancer care and improve patient outcomes.
January 11, 2026 Guardant Health Reports Strong Preliminary Financial Results for Q4 and Full Year 2025 Guardant Health reported strong preliminary financial results for Q4 and 2025, with a 39% revenue increase. The company's innovative Shield screening platform also saw significant growth, positioning Guardant as a leader in precision oncology.
January 08, 2026 Guardant Health Expands Colorectal Cancer Screening Access to U.S. Military Families Guardant Health has announced that its Shield blood test for colorectal cancer screening is now covered for active-duty military members and their families. This FDA-approved, non-invasive test aims to enhance healthcare accessibility and promote early detection among service members aged 45 and older.
December 29, 2025 Guardant Health Set to Present at the 44th Annual J.P. Morgan Healthcare Conference Guardant Health will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, discussing innovations in precision oncology. The event will include a Q&A session and is accessible via webcasts for those unable to attend.
December 22, 2025 Guardant Health Japan Receives Regulatory Approval for Guardant360® CDx: A New Era in Breast Cancer Diagnostics Guardant Health Japan has received regulatory approval for its Guardant360® CDx test, the first blood-based diagnostic for ESR1 mutations in breast cancer. This advancement enhances targeted treatment options and is accessible through Japan’s national health insurance, marking a significant step in precision oncology.
December 11, 2025 Guardant Health Partners with Trial Library to Enhance Cancer Clinical Trial Access Guardant Health has partnered with Trial Library to improve access to oncology clinical trials. This collaboration aims to connect patients with innovative treatments through AI technology, addressing barriers in participation, especially for those in underserved areas.
December 09, 2025 Guardant Health Partners with Policlinico Gemelli to Launch Liquid Biopsy Testing in Italy Guardant Health has launched its FPG 360 liquid biopsy testing service at Policlinico Gemelli in Italy, improving access to precision oncology for cancer patients. This initiative represents a significant step in enhancing local cancer care and is part of Guardant's broader strategy to expand partnerships in Europe.
December 05, 2025 Guardant Health Showcases Advances in Liquid Biopsy Technology at SABCS 2025 Guardant Health will present 14 abstracts at SABCS 2025, showcasing its advanced liquid biopsy technologies for breast cancer. Key findings highlight the efficacy of Guardant Reveal and Guardant360 Liquid in predicting outcomes and customizing patient treatment.
November 12, 2025 Guardant Health Launches Groundbreaking Initiative for Data Interoperability Guardant Health has launched the Single Namespace Working Group, a consortium aimed at establishing a standardized approach to managing exabyte-scale data across industries. This initiative seeks to enhance collaboration and efficiency in data access, crucial for advancements in healthcare and technology.
November 10, 2025 Guardant Health Expands Blood Test Capabilities for Late-Stage Cancer Monitoring Guardant Health has expanded its Guardant Reveal blood test to enhance monitoring for late-stage cancer patients. Utilizing advanced epigenomic technology, the test provides quicker insights into therapy responses, improving patient outcomes significantly. A new universal ordering option further streamlines the process for healthcare providers.
November 07, 2025 Guardant Health, Inc. to Showcase Innovations at Upcoming Investor Conferences Guardant Health, a leader in precision oncology, will participate in two major investor conferences in November and December to discuss its innovations. Webcasts will be available for stakeholders to stay informed about the company's advancements and insights.
November 06, 2025 Guardant Health Unveils Promising Data on Blood Test for Monitoring Chemotherapy Response Guardant Health has unveiled promising data indicating that its Guardant Reveal blood test can monitor chemotherapy responses in advanced solid tumors much earlier than traditional methods. This innovative test correlates tumor signal changes with survival rates, allowing for timely treatment adjustments and potentially improving patient outcomes.
November 06, 2025 Guardant Health Announces Inducement Grants to New Employees Guardant Health has approved significant equity grants for new hires, including RSUs and stock options, to attract and retain talent in the competitive oncology sector. This initiative reflects the company's commitment to building a skilled workforce dedicated to advancing cancer care.
November 05, 2025 Guardant Health's Shield CRC Blood Test Achieves Remarkable 95% Adherence in Landmark Study Guardant Health's Shield blood test for colorectal cancer has achieved an impressive 95% adherence rate in a study involving 20,000 patients. This FDA-approved test offers a simple blood draw option that significantly improves screening rates, especially in underserved areas, highlighting its potential impact on public health.
November 05, 2025 Guardant Health Upsizes Public Offering, Aims for Growth in Precision Oncology Guardant Health has upsized its public offering of common stock to raise about $284.4 million. This strategic move, along with a concurrent notes offering, aims to bolster its financial position in the precision oncology sector.
November 05, 2025 Guardant Health Upsizes Convertible Notes Offering to $350 Million Guardant Health has increased its convertible notes offering to $350 million, showcasing robust investor interest. The proceeds will support corporate initiatives, including potential repurchases of existing notes, as the company continues to lead in precision oncology.
November 04, 2025 Guardant Health Announces Major Public Offering: A $250 Million Initiative Guardant Health has announced a $250 million public offering, with an additional $300 million in convertible senior notes. These initiatives aim to secure funding for general corporate purposes, including potential acquisitions, as the company continues to innovate in precision oncology.
November 04, 2025 Guardant Health Announces $300 Million Convertible Senior Notes Offering Guardant Health is set to offer $300 million in convertible senior notes due 2033 to institutional buyers, alongside a $250 million common stock offering. The proceeds will support general corporate purposes, including potential acquisitions and repurchases of existing notes.
October 29, 2025 Guardant Health Reports Q3 2025 Financial Results and Raises Revenue Guidance Guardant Health's Q3 2025 results show a 39% revenue increase to $265.2M, driven by oncology test volume growth. The company raised its full-year revenue guidance, reflecting strong operational performance and strategic advancements.
October 29, 2025 Guardant Health, Inc. Reports Strong Q3 2025 Results Amidst Ongoing Challenges Guardant Health, Inc. reported a 39% revenue increase for Q3 2025, driven by oncology testing advancements. Despite losses, strategic partnerships and product developments position the company well for future growth in precision oncology.
October 27, 2025 Guardant Health and Zephyr AI Forge Strategic Partnership to Enhance Drug Response Predictions Guardant Health has partnered with Zephyr AI to revolutionize oncology through AI-driven insights and real-world data. This collaboration aims to enhance drug development and improve patient outcomes in cancer treatment.
October 26, 2025 Guardant Health Unveils Promising Data on Blood-Based Cancer Screening at ACG 2025 Guardant Health presented promising data on blood-based cancer screening at ACG 2025, highlighting the Shield test's effectiveness in improving colorectal cancer screening adherence. The test, favored by patients, shows adherence rates over 90%, signaling a significant advancement in cancer detection methods.
October 15, 2025 Guardant Health Unveils Promising Data at ESMO 2025 Guardant Health is set to present 15 accepted abstracts at ESMO 2025, highlighting advancements in cancer care through genomic insights. Key studies include novel applications of Guardant Infinity™, therapy monitoring, and emerging biomarkers in NSCLC, all aimed at improving patient outcomes in precision oncology.
October 09, 2025 Guardant Health Set to Release Third Quarter 2025 Financial Results Guardant Health is set to release its Q3 2025 financial results on October 29, 2025, followed by a conference call to discuss the outcomes. The company, a leader in precision oncology, aims to provide insights into its performance and future strategies, highlighting its commitment to improving cancer care.
September 29, 2025 FDA Approves Guardant360® CDx as Companion Diagnostic for Breast Cancer Treatment Guardant Health's Guardant360 CDx has received FDA approval as a companion diagnostic for Inluriyo, targeting ESR1-mutated advanced breast cancer. This advancement allows for improved precision in identifying suitable candidates for treatment, marking a significant milestone in personalized oncology.
September 24, 2025 Guardant Health and Quest Diagnostics Join Forces to Enhance Colorectal Cancer Screening Guardant Health has partnered with Quest Diagnostics to make the Shield™ blood-based colorectal cancer screening test widely accessible across the U.S. This collaboration aims to enhance early detection and improve patient outcomes, addressing barriers to traditional screening methods.
July 30, 2025 Guardant Health Reports Strong Q2 2025 Results Amid Continued Investment in Precision Oncology Guardant Health reported a 31% increase in Q2 2025 revenue, driven by oncology growth, despite a net loss. The company continues to invest heavily in R&D and expand international partnerships to enhance its market position in precision oncology.
May 08, 2025 Guardant Health's Co-CEOs Named to TIME100 Health List Guardant Health's co-CEOs, Helmy Eltoukhy and AmirAli Talasaz, have been named to the TIME100 Health list for their contributions to oncology. Their innovative Shield blood test promises early cancer detection, enhancing patient care and treatment outcomes. This recognition highlights the company's commitment to transforming cancer screening and management.
May 07, 2025 Guardant Health Announces Inducement Grants Under Nasdaq Rule 5635(c)(4) Guardant Health has approved inducement grants for 139 new non-executive employees, including restricted stock units and stock options, to strengthen its workforce. This strategic move aims to attract top talent and enhance the company's innovation in precision oncology.
April 30, 2025 Guardant Health, Inc. Reports Strong Growth in Q1 2025 Amid Reimbursement Challenges Guardant Health, Inc. announced a revenue increase to $203.5 million in Q1 2025, driven by oncology tests despite a net loss of $95.15 million. The company is actively addressing reimbursement challenges and expanding its international presence to enhance cancer care.
April 30, 2025 Guardant Health Reports Strong Q1 2025 Performance and Raises Revenue Guidance Guardant Health reported a 21% revenue growth in Q1 2025, reaching $203.5 million, driven by significant gains in oncology and biopharma sectors. The company raised its full-year revenue guidance, reflecting strong operational advancements, including new product launches and strategic partnerships.
April 29, 2025 Guardant Health Unveils Promising Data for Shield Multi-Cancer Detection Test Guardant Health unveiled its Shield multi-cancer detection test, demonstrating high specificity and sensitivity, particularly for aggressive cancer types. This innovative test aims to enhance early cancer detection through a simple blood draw, potentially reducing mortality rates significantly.
April 28, 2025 Guardant Health Launches Groundbreaking Guardant360 Tissue Test Guardant Health has launched the Guardant360 Tissue test, pioneering a new approach in cancer diagnostics through comprehensive multiomic analysis. This innovative test reduces tissue requirements and enhances molecular profiling, promising to improve patient outcomes in precision oncology.
April 24, 2025 Guardant Health and Pfizer Join Forces in Oncology Innovation Guardant Health has partnered with Pfizer to enhance cancer treatment through liquid biopsy technology. This collaboration focuses on integrating innovative tests into clinical studies, particularly in China, to improve patient outcomes and advance cancer research.
April 22, 2025 Guardant Health Showcases Innovations in Cancer Detection at AACR 2025 Guardant Health will present 18 abstracts at AACR 2025, highlighting innovations like the Shield™ MCD test and new methylation-based liquid biopsy applications. These advancements aim to enhance multi-cancer detection and improve patient outcomes in precision oncology.
April 10, 2025 Guardant Health to Announce Q1 2025 Financial Results: Key Information Ahead of the Call Guardant Health is set to announce its Q1 2025 financial results on April 30, followed by a conference call. This event will provide critical insights into the company's performance and innovations in precision oncology.
April 03, 2025 Guardant Health Partners with Bayshore HealthCare to Enhance Cancer Care in Canada Guardant Health has partnered with Bayshore HealthCare to improve cancer care accessibility in Canada. This collaboration will integrate advanced precision oncology tests into Bayshore's clinics, enhancing diagnostic options and patient outcomes.
March 25, 2025 Guardant Health's Shield Blood Test Gains Coverage for U.S. Veterans Guardant Health's Shield blood test for colorectal cancer screening has gained coverage under the U.S. Department of Veterans Affairs, expanding access for veterans aged 45 and older. This decision, which eliminates copays for average-risk individuals, marks a significant improvement in veterans' healthcare and early cancer detection efforts.
March 11, 2025 Guardant Health Secures ADLT Status for Shield Blood Test: A Game Changer in Colorectal Cancer Screening Guardant Health's Shield blood test has received ADLT status from CMS, enhancing its role in colorectal cancer screening. This non-invasive test, now covered by Medicare, promises to improve accessibility and patient outcomes in early detection of CRC.
March 05, 2025 Guardant Health Collaborates with Dak Prescott’s Foundation to Enhance Colon Cancer Screening in Louisiana Guardant Health has teamed up with Dak Prescott’s Faith Fight Finish Foundation to improve colorectal cancer screening in underserved Louisiana communities. This initiative includes mobile screenings and the innovative Shield blood test, making access easier for those in need. Upcoming events aim to raise awareness and provide essential testing.
February 28, 2025 Guardant Health Announces Significant Inducement Grants to New Employees Guardant Health has announced substantial inducement grants, including RSUs and stock options, to attract top talent to bolster its workforce. This strategic move aligns with its commitment to advancing cancer care and promoting employee retention.
February 27, 2025 Guardant Health Unveils Survey Results Highlighting Barriers to Colorectal Cancer Screening Guardant Health's latest survey reveals increasing patient anxiety about colorectal cancer screenings, with many avoiding traditional methods. The findings advocate for FDA-approved blood tests as a promising alternative to enhance screening participation and address disparities in healthcare access.
February 20, 2025 Guardant Health, Inc. Reports Strong Growth in 2024 Annual Report Guardant Health, Inc. reported significant revenue growth of 31% in 2024, reaching $739 million, driven by demand for precision oncology testing. The company also launched innovative products, including the FDA-approved Shield blood test, while navigating legal and financial challenges.
February 20, 2025 Guardant Health Reports Impressive Growth in Q4 and Full Year 2024 Results Guardant Health's Q4 2024 results showed a 30% revenue increase to $201.8 million, with a full-year total of $739 million, up 31%. The company anticipates continued growth in 2025, driven by strong oncology product performance and new partnerships.
February 10, 2025 Guardant Health Set to Engage Investors at Key Conferences Guardant Health is set to engage investors at major upcoming conferences, highlighting its innovations in cancer care. The events will provide opportunities for direct interaction with leadership and insights into the company's future initiatives.
February 07, 2025 Guardant Health Announces Significant Debt Exchange Transactions Guardant Health has announced a $600 million debt exchange to restructure its obligations, issuing new convertible notes while planning significant share repurchases. This move aims to optimize capital structure and bolster financial flexibility in the evolving oncology landscape.
February 05, 2025 SWOT Analysis of Guardant Health, Inc. in 2025 This SWOT analysis evaluates Guardant Health, Inc.'s strategic position in 2025, highlighting its technological leadership and extensive product portfolio, while addressing financial losses and intense competition. The analysis outlines opportunities for market expansion and new product development amidst regulatory challenges.
November 06, 2024 Guardant Health, Inc. Reports Q3 2024 Financial Results Guardant Health, Inc. reported Q3 2024 revenues of $191.5 million, a 34% increase year-over-year, driven by new product launches. Despite facing operational challenges and a net loss, the company's commitment to innovation in precision oncology remains strong.
August 07, 2024 Guardant Health, Inc. Reports Strong Q2 2024 Results Amid Milestone FDA Approval Guardant Health, Inc. showcased strong growth with $177.2 million in Q2 2024 revenues, a 29% increase year-over-year. The FDA's approval of the Shield blood test for colorectal cancer screening marks a significant milestone, despite a net loss of $102.6 million attributed to rising expenses.
May 09, 2024 Guardant Health, Inc. Reports Impressive Q1 2024 Financial Results Guardant Health reported a 31% revenue increase in Q1 2024, reaching $168.5 million, driven by a surge in precision oncology testing. Despite a net loss, the company is strategically positioned for future growth with ongoing investments in R&D and international expansion.
